The UC indication selection and Phase 1 immune modulation data are positive catalysts, but the trial is not expected to start until 2027 and is contingent on additional capital. Monitor the August 19 KOL webinar for further data and any financing updates. The ongoing REVERT HCC Phase 1b/2 topline data expected 2H:2026 is a nearer-term catalyst.
Price Chart
Executive Summary
Tvardi Therapeutics announced the selection of ulcerative colitis (UC) as the initial indication for TTI-109, its next-generation STAT3 inhibitor, following a Phase 1 healthy volunteer study that showed placebo-adjusted reductions in Th17, Tfh, and B cell populations implicated in UC pathology. The company plans to initiate a Phase 1b/2 trial in moderate-to-severe UC in 2027, subject to IND clearance and additional funding. The filing also included an updated corporate presentation highlighting TTI-109's improved GI tolerability over TTI-101 and its differentiated safety profile vs. JAK inhibitors.
Key Facts
- TTI-109 selected as lead candidate for ulcerative colitis (UC) as initial indication
- Phase 1 healthy volunteer study showed placebo-adjusted reductions in Th17 (up to 76%), Tfh (up to 43%), and B cell (up to 71%) subsets implicated in UC pathology
- TTI-109 demonstrated rapid conversion to active moiety TTI-101, equivalent exposures at molar equivalent doses, and diarrhea duration comparable to placebo (mean 0.47 days vs. 1.19 days for placebo and 3.35 days for TTI-101 400mg BID)
- Planned UC trial initiation in 2027, subject to IND clearance and additional funding; primary endpoint safety, secondary endpoint clinical remission at 12 weeks
- More than 400 subjects dosed across Tvardi's STAT3 inhibitor programs with differentiated safety profile from JAK inhibitors
- UC market: >1.25M diagnosed US patients, ~$3B US market, ~$9B global market; >70% of patients do not achieve clinical remission with existing therapies
- TTI-109 achieved >8-fold greater drug concentration in colon tissue vs. plasma in preclinical UC models
- Company to host KOL webinar with Dr. Randy Longman on August 19, 2026
Financial Impact
No financial figures reported in filing. UC represents a ~$3B US and ~$9B global addressable market, but Tvardi is pre-revenue and trial initiation is contingent on additional funding.
Risk Factors
- Trial initiation in 2027 is subject to IND clearance and additional funding, which may not be available on favorable terms
- Phase 1 data is in healthy volunteers, not UC patients; efficacy in UC is unproven
- Small market cap ($27M) and pre-revenue status create financing risk
- Competitive UC landscape with multiple approved therapies (anti-TNF, JAK inhibitors, S1P modulators) achieving <30% placebo-adjusted remission rates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-088461 |
| Document: tm2621651d1_8k.htm | 0001104659-26-088461 |
| Document: tm2621651d1_ex99-1.htm | 0001104659-26-088461 |
| Document: 0001104659-26-088461-index-headers.html | 0001104659-26-088461 |
| Document: 0001104659-26-088461-index.html | 0001104659-26-088461 |
| Document: 0001104659-26-088461.txt | 0001104659-26-088461 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | Institutional Cluster | $1.86 $1.61 | ▲ +13.44% | ▲ +12.91% | $0.8653 (+53.48%) |
Aug 14, 2026 10w ago | 8-K | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8653 (−54.46%) |
Aug 14, 2026 10w ago | Press Release | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8653 (−54.46%) |
Jul 30, 2026 12w ago | 8-K | $2.10 $1.80 | ▼ −14.29% | ▼ −18.25% | $0.8653 (−58.80%) |
Jul 7, 2026 16w ago | 8-K | $3.10 $2.02 | ▼ −34.84% | ▼ −36.17% | $0.8653 (−72.09%) |
May 14, 2026 23w ago | EFFECT | $3.96 $2.64 | ▲ +33.33% | ▲ +32.48% | $0.8653 (+78.15%) |
May 13, 2026 23w ago | EFFECT | $3.95 $2.71 | ▲ +31.39% | ▲ +30.78% | $0.8653 (+78.09%) |
May 8, 2026 24w ago | Press Release | $4.18 $2.89 | ▼ −30.86% | ▼ −30.88% | $0.8653 (−79.30%) |
Apr 23, 2026 26w ago | DEFA14A | $3.10 $3.59 | ▲ +15.81% | ▲ +11.78% | $0.8653 (−72.09%) |
Mar 31, 2026 30w ago | 8-K | $3.00 $3.06 | ▲ +2.00% | ▼ −7.72% | $0.8653 (−71.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers